Serum levels of the tumour‐associated trypsin inhibitor in patients with endometriosis
Objective To show that in patients with endometriosis a 6 kD polypeptide, the tumour‐associated trypsin inhibitor (TATI), can occur at elevated concentrations in serum. Design In a prospective study TATI serum levels were assessed prior to surgery in 368 consecutive patients suffering from benign gy...
Saved in:
Published in | BJOG : an international journal of obstetrics and gynaecology Vol. 104; no. 1; pp. 78 - 81 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.01.1997
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective
To show that in patients with endometriosis a 6 kD polypeptide, the tumour‐associated trypsin inhibitor (TATI), can occur at elevated concentrations in serum.
Design
In a prospective study TATI serum levels were assessed prior to surgery in 368 consecutive patients suffering from benign gynaecological diseases (e.g. pelvic pain, infertility, elective sterilisation, uterine fibroids and pelvic masses) with (n= 71) and without (n= 297) endometriosis, who underwent laparoscopy or laparotomy for diagnosis and/or treatment.
Results
The TATI serum levels of patients suffering from endometriosis were significantly different from those in the control group and showed a positive correlation with the stage of endometriosis. The sensitivity of TATI was 0.34 with a specificity of 0.85 for all cases of endometriosis, with an increase of sensitivity (0.67) and slight decrease of specificity (0.82), considering only a group of Stage III/IV patients. Excluding patients with benign ovarian cysts, the specificity of TATI was 0.91 and 0.85, respectively. The combination of TATI and CA125 showed an increase of sensitivity to 0.59 for all cases of endometriosis and 0.89 for patients with Stage III/IV endometriosis.
Conclusions
The sensitivity of TATI as a screening method for endometriosis is too low, but considering its high specificity, TATI in combination with CA125 could provide an additional diagnostic tool in diagnosis and follow up of patients with endometriosis. |
---|---|
AbstractList | To show that in patients with endometriosis a 6 kD polypeptide, the tumour-associated trypsin inhibitor (TATI), can occur at elevated concentrations in serum.
In a prospective study TATI serum levels were assessed prior to surgery in 368 consecutive patients suffering from benign gynaecological diseases (e.g. pelvic pain, infertility, elective sterilisation, uterine fibroids and pelvic masses) with (n = 71) and without (n = 297) endometriosis, who underwent laparoscopy or laparotomy for diagnosis and/or treatment.
The TATI serum levels of patients suffering from endometriosis were significantly different from those in the control group and showed a positive correlation with the stage of endometriosis. The sensitivity of TATI was 0.34 with a specificity of 0.85 for all cases of endometriosis, with an increase of sensitivity (0.67) and slight decrease of specificity (0.82), considering only a group of Stage III/IV patients. Excluding patients with benign ovarian cysts, the specificity of TATI was 0.91 and 0.85, respectively. The combination of TATI and CA125 showed an increase of sensitivity to 0.59 for all cases of endometriosis and 0.89 for patients with Stage III/IV endometriosis.
The sensitivity of TATI as a screening method for endometriosis is too low, but considering its high specificity, TATI in combination with CA125 could provide an additional diagnostic tool in diagnosis and follow up of patients with endometriosis. Objective To show that in patients with endometriosis a 6 kD polypeptide, the tumour‐associated trypsin inhibitor (TATI), can occur at elevated concentrations in serum. Design In a prospective study TATI serum levels were assessed prior to surgery in 368 consecutive patients suffering from benign gynaecological diseases (e.g. pelvic pain, infertility, elective sterilisation, uterine fibroids and pelvic masses) with ( n = 71 ) and without ( n = 297 ) endometriosis, who underwent laparoscopy or laparotomy for diagnosis and/or treatment. Results The TATI serum levels of patients suffering from endometriosis were significantly different from those in the control group and showed a positive correlation with the stage of endometriosis. The sensitivity of TATI was 0.34 with a specificity of 0.85 for all cases of endometriosis, with an increase of sensitivity (0.67) and slight decrease of specificity (0.82), considering only a group of Stage III/IV patients. Excluding patients with benign ovarian cysts, the specificity of TATI was 0.91 and 0.85, respectively. The combination of TATI and CA125 showed an increase of sensitivity to 0.59 for all cases of endometriosis and 0.89 for patients with Stage III/IV endometriosis. Conclusions The sensitivity of TATI as a screening method for endometriosis is too low, but considering its high specificity, TATI in combination with CA125 could provide an additional diagnostic tool in diagnosis and follow up of patients with endometriosis. Objective To show that in patients with endometriosis a 6 kD polypeptide, the tumour‐associated trypsin inhibitor (TATI), can occur at elevated concentrations in serum. Design In a prospective study TATI serum levels were assessed prior to surgery in 368 consecutive patients suffering from benign gynaecological diseases (e.g. pelvic pain, infertility, elective sterilisation, uterine fibroids and pelvic masses) with (n= 71) and without (n= 297) endometriosis, who underwent laparoscopy or laparotomy for diagnosis and/or treatment. Results The TATI serum levels of patients suffering from endometriosis were significantly different from those in the control group and showed a positive correlation with the stage of endometriosis. The sensitivity of TATI was 0.34 with a specificity of 0.85 for all cases of endometriosis, with an increase of sensitivity (0.67) and slight decrease of specificity (0.82), considering only a group of Stage III/IV patients. Excluding patients with benign ovarian cysts, the specificity of TATI was 0.91 and 0.85, respectively. The combination of TATI and CA125 showed an increase of sensitivity to 0.59 for all cases of endometriosis and 0.89 for patients with Stage III/IV endometriosis. Conclusions The sensitivity of TATI as a screening method for endometriosis is too low, but considering its high specificity, TATI in combination with CA125 could provide an additional diagnostic tool in diagnosis and follow up of patients with endometriosis. |
Author | Buxbaum, Pia Leodolter, Sepp Ogris, Emil Peters‐Engl, Christian Medl, Michael Mierau, Michael |
Author_xml | – sequence: 1 givenname: Michael surname: Medl fullname: Medl, Michael – sequence: 2 givenname: Emil surname: Ogris fullname: Ogris, Emil – sequence: 3 givenname: Christian surname: Peters‐Engl fullname: Peters‐Engl, Christian – sequence: 4 givenname: Michael surname: Mierau fullname: Mierau, Michael – sequence: 5 givenname: Pia surname: Buxbaum fullname: Buxbaum, Pia – sequence: 6 givenname: Sepp surname: Leodolter fullname: Leodolter, Sepp |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/8988701$$D View this record in MEDLINE/PubMed |
BookMark | eNqVkMtKAzEUhoNUalt9BCG4nzGZzC2CCy1eKXShgruQzJyhKXMjydh25yP4jD6JM7a492zODx__v_imaFQ3NSB0QYlP-7tc-zRMqEeiIPUp54nvFCVxxPztEZr8odFvJh5hQXqCptauCaFxQNgYjVOepgmhE_T-AqarcAkfUFrcFNitALuuajrz_fklrW0yLR3k2Jlda3WNdb3SSrvG9Am30mmoncUb7VYY6rypwBndWG1P0XEhSwtnhz9Db_d3r_NHb7F8eJrfLLyM8ST1ABKlIiWlylhOqKR5WoQ0CFTIKc0UqJzFHCIZFJwQFkYRKA6xCiLIEh4nMZuhq_1uZhprDRSiNbqSZicoEYMtsRaDEjEoEYMtcbAltn35fF9uO1VB_lc96On59Z5vdAm7fyyL2-dlkrIf8G5_Wg |
CitedBy_id | crossref_primary_10_1016_j_cccn_2003_10_021 crossref_primary_10_1016_S0015_0282_00_01580_6 crossref_primary_10_1093_humupd_dmq009 crossref_primary_10_1016_S0015_0282_98_00355_0 crossref_primary_10_1111_j_1471_0528_1997_tb14366_x crossref_primary_10_5653_cerm_2011_38_3_164 crossref_primary_10_1007_s12262_010_0087_3 crossref_primary_10_3349_ymj_2015_56_4_1079 crossref_primary_10_1002_14651858_CD012179 crossref_primary_10_1016_S0889_8529_03_00045_8 crossref_primary_10_1093_humrep_deh890 crossref_primary_10_2217_whe_15_44 crossref_primary_10_3390_biomedicines10102558 crossref_primary_10_1111_1471_0528_14055 |
Cites_doi | 10.1038/bjc.1995.202 10.1016/S0015-0282(16)60185-1 10.1038/bjc.1990.64 10.1002/ijc.2910310606 10.1016/S0015-0282(16)48430-X 10.1093/clinchem/35.5.869 10.1002/ijc.2910300110 10.1016/S0021-9258(18)33505-1 10.1016/S0015-0282(16)49333-7 10.1016/S0021-9258(18)71648-7 10.1016/S0015-0282(16)49390-8 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1111/j.1471-0528.1997.tb10653.x |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-0528 |
EndPage | 81 |
ExternalDocumentID | 10_1111_j_1471_0528_1997_tb10653_x 8988701 BJO78 |
Genre | miscellaneous Journal Article |
GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1B1 1OB 1OC 1~5 23N 24P 33P 36B 3O- 3SF 4.4 4G. 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5RE 5VS 66C 6J9 6P2 6PF 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANLZ AAONW AAQFI AASGY AAWTL AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIUM ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADMUD ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DUUFO EBS EJD EMOBN EX3 F00 F01 F04 F5P FDB FEDTE FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NEJ NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIG RIWAO RJQFR ROL RPZ RWI RX1 SAMSI SEW SSZ SUPJJ TEORI V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 XIF XV2 ZXP ZY1 ~IA ~WT AAIKC AAMNW AAQQT AAQXK ABJNI AFFNX AFTJW AI. AKRWK CGR CUY CVF ECM EIF FGOYB NPM NQ- OZT R2- UHS VH1 WH7 WUP ZGI ZZTAW AAYXX CITATION |
ID | FETCH-LOGICAL-c3978-ee7bb5baabc3d01a1d8f4122b4911cbebd369e5a2f9003455eb9e6b25ec796763 |
IEDL.DBID | DR2 |
ISSN | 1470-0328 0306-5456 |
IngestDate | Fri Aug 23 03:38:32 EDT 2024 Sat Sep 28 08:33:38 EDT 2024 Sat Aug 24 01:04:42 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3978-ee7bb5baabc3d01a1d8f4122b4911cbebd369e5a2f9003455eb9e6b25ec796763 |
PMID | 8988701 |
PageCount | 4 |
ParticipantIDs | crossref_primary_10_1111_j_1471_0528_1997_tb10653_x pubmed_primary_8988701 wiley_primary_10_1111_j_1471_0528_1997_tb10653_x_BJO78 |
PublicationCentury | 1900 |
PublicationDate | January 1997 1997-Jan 1997-01-00 |
PublicationDateYYYYMMDD | 1997-01-01 |
PublicationDate_xml | – month: 01 year: 1997 text: January 1997 |
PublicationDecade | 1990 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: England |
PublicationTitle | BJOG : an international journal of obstetrics and gynaecology |
PublicationTitleAlternate | Br J Obstet Gynaecol |
PublicationYear | 1997 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | 1983; 31 1985; 80 1995; 71 1988; 50 1982; 257 1989; 35 1985; 43 1986; 45 1982; 30 1989; 264 1990; 61 9255096 - Br J Obstet Gynaecol. 1997 Aug;104(8):970-1 Matsuda K (e_1_2_5_10_2) 1985; 80 e_1_2_5_13_2 e_1_2_5_9_2 e_1_2_5_8_2 e_1_2_5_6_2 e_1_2_5_5_2 e_1_2_5_4_2 e_1_2_5_11_2 e_1_2_5_3_2 e_1_2_5_2_2 Huhtala ML (e_1_2_5_7_2) 1982; 257 Paavonen J (e_1_2_5_12_2) 1989; 35 |
References_xml | – volume: 71 start-page: 1051 year: 1995 end-page: 1054 article-title: TATI (tumor‐associated trypsin inhibitor) as a marker of ovarian cancer publication-title: Br J Cancer – volume: 257 start-page: 13 year: 1982 article-title: Purification and characterization of a tumor‐associated trypsin inhibitor from the urine of a patient with ovarian cancer publication-title: J Biol Chem – volume: 45 start-page: 770 year: 1986 end-page: 773 article-title: CA125 levels in endometriosis publication-title: Fertil Steril – volume: 80 start-page: 694 year: 1985 end-page: 698 article-title: Postoperative elevation of pancreatic secretory trypsin inhibitor publication-title: Am J Gastroenterol – volume: 31 start-page: 711 year: 1983 end-page: 714 article-title: Excretion of a tumor‐ associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy publication-title: Int J Cancer – volume: 35 start-page: 869 year: 1989 end-page: 871 article-title: Concentrations of tumor‐associated trypsin inhibitor and C‐reactive protein in serum in acute pelvic inflammatory disease publication-title: Clin Chem – volume: 30 start-page: 53 year: 1982 end-page: 57 article-title: Immunohistochemical demonstration of an ovarian cancer associated urinary peptide publication-title: Int J Cancer – volume: 61 start-page: 327 year: 1990 end-page: 329 article-title: Tumor associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in mucinous ovarian tumors publication-title: Br J Cancer – volume: 50 start-page: 573 year: 1988 end-page: 579 article-title: Tumor necrosis factor in peritoneal fluid of women undergoing laparascopic surgery publication-title: Fertil Steril – volume: 43 start-page: 351 year: 1985 end-page: 352 article-title: Revised American Fertility Society Classification of endometriosis publication-title: Fertil Steril – volume: 264 start-page: 14095 year: 1989 end-page: 14099 article-title: Human ovarian tumor‐associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro‐urokinase publication-title: J Biol Chem – volume: 45 start-page: 630 year: 1986 end-page: 634 article-title: Elevated serum concentrations of CA125 in patients with advanced endometriosis publication-title: Fertil Steril – ident: e_1_2_5_5_2 doi: 10.1038/bjc.1995.202 – ident: e_1_2_5_13_2 doi: 10.1016/S0015-0282(16)60185-1 – volume: 80 start-page: 694 year: 1985 ident: e_1_2_5_10_2 article-title: Postoperative elevation of pancreatic secretory trypsin inhibitor publication-title: Am J Gastroenterol contributor: fullname: Matsuda K – ident: e_1_2_5_11_2 doi: 10.1038/bjc.1990.64 – ident: e_1_2_5_8_2 doi: 10.1002/ijc.2910310606 – ident: e_1_2_5_4_2 doi: 10.1016/S0015-0282(16)48430-X – volume: 35 start-page: 869 year: 1989 ident: e_1_2_5_12_2 article-title: Concentrations of tumor‐associated trypsin inhibitor and C‐reactive protein in serum in acute pelvic inflammatory disease publication-title: Clin Chem doi: 10.1093/clinchem/35.5.869 contributor: fullname: Paavonen J – ident: e_1_2_5_6_2 doi: 10.1002/ijc.2910300110 – volume: 257 start-page: 13 year: 1982 ident: e_1_2_5_7_2 article-title: Purification and characterization of a tumor‐associated trypsin inhibitor from the urine of a patient with ovarian cancer publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)33505-1 contributor: fullname: Huhtala ML – ident: e_1_2_5_3_2 doi: 10.1016/S0015-0282(16)49333-7 – ident: e_1_2_5_9_2 doi: 10.1016/S0021-9258(18)71648-7 – ident: e_1_2_5_2_2 doi: 10.1016/S0015-0282(16)49390-8 |
SSID | ssj0016203 ssj0007764 |
Score | 1.6348238 |
Snippet | Objective
To show that in patients with endometriosis a 6 kD polypeptide, the tumour‐associated trypsin inhibitor (TATI), can occur at elevated concentrations... To show that in patients with endometriosis a 6 kD polypeptide, the tumour-associated trypsin inhibitor (TATI), can occur at elevated concentrations in serum.... |
SourceID | crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 78 |
SubjectTerms | Biomarkers, Tumor - blood CA-125 Antigen - blood Cysts - blood Endometriosis - blood Female Humans Leiomyomatosis - blood Pelvic Inflammatory Disease - blood Predictive Value of Tests Sensitivity and Specificity Trypsin Inhibitor, Kazal Pancreatic - blood Uterine Neoplasms - blood |
Title | Serum levels of the tumour‐associated trypsin inhibitor in patients with endometriosis |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1471-0528.1997.tb10653.x https://www.ncbi.nlm.nih.gov/pubmed/8988701 |
Volume | 104 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NatwwEBZhD6WXJm0Tsk1SdOjVi39k2T4mIcsS2G0JCezNaOQxNel6w9oLTU55hDxjniQztrKkgR5acjEGewTSSDOfRqNvhPiWAvDhlfEIPaSe0qQLCLPSI9-vC1OiLbvQwHSmJ1fqfB7P3fVovgvT80NsAm68Mjp7zQvcQPNqkSe0FY7DlK_cJaMWAiZaHTGiZGY9RkgXGy6pQIddmWQS8j0mkXMMpC6t5y9N_eGtNi7qJYzt_NB4Wyyee9Cnn1yP1i2M7N0rcse36uKO-OAAqzzuZ9hHsYX1J_Fu6o7kP4s5WZv1Qv7i5KNGLktJiFK26wXJPd4_GKd9LGS7ur1pqlpW9c8KyI6s6E06WtdGcjxYYl0sF1zia9lUza64Gp9dnk48V67BsxHvRRETgBiMARsVfmCCIi1VEIagyKBaQCginWFswpKjpyqOETLUEMZok0yTndsTg3pZ476QKlIYoba2MKiCxKYRRuAD_UMfFGZDET2rJb_pWTnyl7uZJMh50HIetNwNWv57KPZ6DW5k0oxsrB8Mhe7U8A9t5Sfn35P0y_8KHoj3PQ8ux3IOxaBdrfGI0E0LX7tZS8_Zj-kTFpXwIw |
link.rule.ids | 315,786,790,1382,27955,27956,46327,46751 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bS-tAEB7EA-qLxyv2eNsHX1OaZLNJHr1SL1UQhb6FzGaCRZuWJgWPT_4Ef6O_xNkkLSr4oPgW2MzCzuxcd_ZbgL0A0RxexRZHD4ElFcsCnTC12PerJE5Jp2VpoHOp2rfyrOt1Z6AzuQtT4UNMC25GM0p7bRTcFKQ_abnPubDnBObOnd8s0DZIq00OKf-w_ntGT4-up2hStnLKh5KZqmUZGLkag7Ru7Plirg_-auqk3geypSc6-QvZZA1VA8p9c1xgUz99gnf8tUUuwWIds4r9apMtwwxlKzDXqU_lV6HLBmfcFw-m_ygXg1RwUCmKcZ_pXp9f4noDUCKK0f9h3stEL7vrIZuSEX-JGtk1F6YkLChLBn3zytcg7-VrcHtyfHPYtuoXGyztmnSUyEf0MI5Ru0nLju0kSKXtOCjZpmokTFwVkhc7qSmgSs8jDEmh45H2Q8Wmbh1ms0FGGyCkK8klpXUSk7R9HbjkYgv5Hx6QFDbAncglGlbAHNH7hMa3I8O0yDAtqpkWPTZgvRLhlCYI2cy27AaoUg7fmCs6OLvyg38_JdyF-fZN5yK6OL0834SFChbXlHa2YLYYjWmbg50Cd8ot_AaDmfM3 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA6iIF58i-szB69dtk2atkdfi29FFPZWOukUF93usu2CevIn-Bv9JU7auKjgQfFWSCeQmWRemXzD2E4IYC6vEoe8h9CRimQBXpQ5ZPtVmmSosyo1cH6hjm7lScfv2OfR5i1MjQ8xTriZk1Hpa3PAB2n27ZAHFAr7Xmie3AXNElwDtNokj3JKKuGZUOzgegwm5Sqv6pNMVC3HoMhZCFJb1_PDXF_M1dhGffZjK0PUnmO9jyXU9Sf3zVEJTf38Dd3xv9Y4z2atx8p36y22wCYwX2TT5_ZOfol1SN2MevzBVB8VvJ9xcil5OeoR3dvLa2LFjykvh0-Dopvzbn7XBVIkQ_riFte14CYhzDFP-z3T46tfdItldts-vNk_cmy_BkcLE4wiBgA-JAlokbbcxE3DTLqeB5I0qgaEVKgI_cTLTPpU-j5ChAo8H3UQKVJ0K2wy7-e4yrgUEgUqrdMEpRvoUKCAFtA_NCAxajDxIZZ4UMNyxJ_DmcCNDdNiw7TYMi1-bLCVWoJjmjAiJdtyG0xVYvjFXPHeyWUQrv2VcJtNXx2047Pji9N1NlNj4pq8zgabLIcj3CRPp4StagO_A6_v8eY |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+levels+of+the+tumour%E2%80%90associated+trypsin+inhibitor+in+patients+with+endometriosis&rft.jtitle=BJOG+%3A+an+international+journal+of+obstetrics+and+gynaecology&rft.au=Medl%2C+Michael&rft.au=Ogris%2C+Emil&rft.au=Peters%E2%80%90Engl%2C+Christian&rft.au=Mierau%2C+Michael&rft.date=1997-01-01&rft.issn=1470-0328&rft.eissn=1471-0528&rft.volume=104&rft.issue=1&rft.spage=78&rft.epage=81&rft_id=info:doi/10.1111%2Fj.1471-0528.1997.tb10653.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_1471_0528_1997_tb10653_x |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-0328&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-0328&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-0328&client=summon |